Search Results

Eli Lilly and Company announced updated clinical data from the international Phase 1/2 BRUIN trial of pirtobrutinib, a non-covalent Bruton’s tyrosine kinase inhibitor, in adult patients with a range of B-cell malignancies.

Bruin Biometrics LLC announces repeated formal recognition of the role of sub-epidermal moisture in the identification of the increased risk of pressure injuries and of the Provizio SEM Scanner in the detection, and guided treatment of SEM for the prevention of broken skin pressure injuries.

According to Jake Van Naarden, president of Lilly Oncology, the excess deaths could be due to the high rate of crossover in BRUIN CLL-321.

Bruin Biometrics LLC (BBI), has agreed for Arjo (ARJO-B.ST), a market-leading supplier of medical devices and solutions, to acquire an equity stake in Bruin Biometrics.

MMS, a leading, data-focused clinical research organization (CRO), announced today that the company has expanded its biometrics leadership within European

Loxo@Lilly, the oncology unit of Eli Lilly and Company (NYSE: LLY), today announced that The New England Journal of Medicine (NEJM) published detailed results from the BRUIN Phase 1/2 trial evaluating the efficacy and safety of an investigational use of pirtobrutinib, a non-covalent (reversible) Bruton’s tyrosine kinase (BTK) inhibitor, in adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who were previously treated with a BTK inhibitor.